A selection of our Laboratory Partners
Agendia B.V.Opaldia is the UK's exclusive partner to Agendia, who have developed high-quality diagnostic methods, using microarray gene expression profiling, for analyzing tumor samples and determining the tumour's specific properties. For MammaPrint, the result is a reliable prediction whether an individual patient is at high or low risk of disease recurrence. In addition, Agendia also offers services aimed at identifying the primary tumor in patients diagnosed with distant metastasis.
Agendia's innovative, yet robust, methods provide physicians and patients with crucial information for determining the optimal treatment plan based on personalised gene expression information thus significantly enhancing the chances for success. At the same time the MammaPrint test enable physicians to minimise their patient's morbidity and expenses associated with more invasive diagnostic procedures.
Genzyme GeneticsGenzyme Genetics is the dynamic global leader in diagnostic genetic testing. They are dedicated to providing high quality services to their clients. From their broad menu of reproductive/genetics and oncology/pathology tests to their world renowned medical staff, Genzyme Genetics has the resources and experience to help our patients receive the most advanced genetic testing available. Opaldia has full access to all of Genzyme’s tests & resources.
Lab21Lab 21 offers a unique and fast growing portfolio of cutting-edge molecular diagnostics, genetics and pharmacogenetic tests. Lab21 has an exclusive partnership with Myriad Genetic Laboratories for the provision of genetic susceptibility testing for breast, ovarian, colorectal, endometrial and skin cancer in the UK and Ireland. Opaldia and Lab 21 are forming strong links to ensure UK patients have access to the latest gold-standard genetic and molecular tests and clinical back-up.
InterGenetics® InterGenetics® is a predictive medicine company focused on molecular diagnostics and targeted therapy for cancer. We have a convergent business model with technology that results in predictive cancer-risk tests and identification of drug leads for targeted cancer treatment.
Laboratory of Molecular Medicine, Harvard Medical School
The Laboratory for Molecular Medicine (LMM) is a CLIA-certified clinical diagnostic laboratory operating within the Harvard Medical School. The LMM received its final regulatory approval and began offering testing services in November of 2003. The mission of the LMM is to bridge the gap between research and clinical medicine, translating novel discoveries into cutting-edge tests and accelerating the adoption of new molecular tests into clinical care. 
University College London Hospital
UCL Hospitals Pathology is committed to delivering a fully accredited, rapid, user friendly and responsive Pathology service. UCLH Pathology's aim is to support all users to deliver top quality patient care and to aid excellent education and world class research.
City Of Hope
The City of Hope Clinical Molecular Diagnostic Laboratory is certified under the Clinical Laboratory Improvements Amendments of 1988 and is licensed by the State of California (CLF 268). The laboratory operates under the clinical license to Lawrence Weiss, M.D., Director of Pathology Laboratories. The laboratory participates in the CAP Molecular Genetics Survey and has a regular program for blinded sample exchange.